Epicrispr Bio

@AjaxDumas Hi @AjaxDumas, we recommend that you sign up for the FSHD Society's patient registry to be alerted of upcoming trials where you can enroll. You can also keep updated with news by subscribing to email updates on our News page or following us on our social media channels.

The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to EPI-321 for the treatment of facioscapulohumeral muscular dystrophy (FSHD), the most common form of muscular dystrophy in adults. Read more here: ow.ly/g6p050Q88Qz

@sierraptrider Can someone email a PDF copy of the latest schedule to info@epic-bio.com?

We are pleased to share that Epic Bio CEO Dr. Amber Salzman has been invited to present at the 2023 Stiefel Healthcare Conference. Read more here: ow.ly/hqtp50Q4QeO

@Epicbiotech partners with @KitePharma to extend the potential application of Epic’s platform for cancer treatment. Epic’s approach is promising for in vivo medicines and may enable next-generation cell therapies #epigenetics #CellTherapy #Cancer

This week at #ESGCT23, Epic Bio presented improvements to CasMINI, previously the smallest Cas protein known to work in human cells. We also shared progress of our epigenetic editing platform and EPI-321 for the treatment of FSHD. Read more here: ow.ly/gFV750Q1aSG

We are pleased to share that Epic Bio will present at the European Society of Gene and Cell Therapy conference October 24-27 in Brussels, Belgium. Read more here: ow.ly/pZup50PYFuR #epigenetics #FSHD #EpicBio

Epic Bio strengthens the leadership team by appointing Weston Miller as Chief Medical Officer. Read more here: ow.ly/v8JN50PXKKv #epigenetics #genomics #FSHD #EpicBio

It was great to attend #FierceBiotechSummit today and be honored for our #Fierce15 win. Thanks, @FierceBiotech, for the recognition and @LifeSciEvents, for the nice trophy we’ll display in our office! #FSHD #EpicBio #epigenetics

"🌍✨ Today is #WorldSightDay, a global initiative to raise awareness about vision impairment and blindness. Sight is a precious gift, and together, we can work towards a world where everyone can see the beauty around them. 👁️ #LoveYourEyes #EpicBio #Epigenetics

CEO, Amber Salzman, Ph.D., will present at the BMO Private Company Showcase on Thursday, October 12, 2023, in New York, NY. Institutional investors interested in meeting with management during the conference may contact their BMO representative. ow.ly/JPx750PTxF1

We are pleased to share that Epic Bio will present at the International Annual Congress of the World Muscle Society. Read more here: ow.ly/ACTr50PQJ2X #FSHD #WMS2023 #EpicBio #musculardystrophy

We are pleased to share that Epic Bio will present at the International Annual Congress of the World Muscle Society. Read more here: epic-bio.com/news/ #FSHD #WMS2023 #EpicBio #musculardystrophy

🔬 Epic Bio is seeking highly motivated Research Associates, Senior Research Associates and Scientists to expand our efforts in developing transformative therapies for patients. 🔬 epic-bio.com/careers/ #Epigenetics #Jobs #ResearchOpportunity #JoinOurTeam #GeneRegulation

ICYMI: 🚀 Epic Bio was recently named in Fierce Biotech's Fierce 15 list! 🏆🧬 #EpicBio #Fierce15 #BiotechInnovation #epigenetics #FSHD ow.ly/O2Eo50PNsIc

ICYMI: 🚀 Epic Bio was recently named in Fierce Biotech's Fierce 15 list! 🏆🧬 #EpicBio #Fierce15 #BiotechInnovation #epigenetics #FSHD ow.ly/O2Eo50PNsIc

Epic Bio CEO, Amber Salzman, Ph.D. will participate in a panel discussion titled “Recent Advances in Epigenetic Editing” at the BMO Spotlight Series on September 26 at 1:00 p.m. ET. ow.ly/wPTi50PNnUe #epigenetics #FSHD #EpigeneticEditing #genetherapy

ICYMI: Epic Bio scientists recently published two papers, "Discovery and engineering of hypercompact epigenetic modulators for durable gene activation" and "Improving few-shot learning-based protein engineering with evolutionary sampling." Read more here: ow.ly/fZiI50PLGKC

We're honored to be named a #Fierce15 winner by @FierceBiotech! We’ve had a momentous year building our #EpigeneticEditing platform and advancing toward clinical entry early next year. And we’ve got much more in store! Follow for updates & read more here: bit.ly/3YPaOUR

We're proud to have presented 6 posters at @CSHL's Genome Engineering: #CRISPR Frontiers conference! The data show dramatic progress of our GEMS #EpigeneticEditing platform, incl. novel hypercompact Cas effectors we've developed. Read more: bit.ly/45bmmEb #cshlCRISPR23